Építés alatt – nem éles oldal
Belépés
Még nem keres résztvevőt itt: Egyesült Államok2. fázis

Prevention of COVID-19 Infection to Severe Pneumonia or ARDS

A legfontosabb adatok

Ki végzi
Enzychem Lifesciences Corporation
Hol
The Bronx és Warwick (Egyesült Államok)Mind a 2 helyszín megnézése
Azonosító
Állapot
Toborzás még nem indult
Fázis
2. fázis
Résztvevők
60 fő, tervezett
Kezdés
2026. dec. 30.
Várható befejezés
2028. jan. 1.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • EC-18
  • Placebo
A regiszteradat frissítve
2026. október 21.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 2 feltétel megnézéseKevesebb

Ki vehet részt

  • Subjects must meet all of the following criteria:; Male or female ≥18 years old; Subjects with confirmed diagnoses of pneumonia caused by COVID-19 from:; RT-PCR or Abbott ID Now COVID-19 test; Chest X-ray or computed tomography (CT) scan (findings of the increased opacity on a chest X-ray, ground-glass opacity indicative of pneumonia on CT, opinion on consolidation, etc.); Those who can tolerate oral administration; Those who do not need oxygen therapy or only need low-flow oxygen (at least 4L/min) but not requiring high-flow oxygen (higher than 4-6L/min) or non-invasive/invasive ventilation primarily according to the WHO guidance; Those who are planned to be hospitalized or who are just hospitalized; Those who have been fully explained about this clinical study and have voluntarily agreed to participate in this clinical study by signing the informed consent form (ICF)

Ki nem vehet részt

  • Subjects cannot participate in this clinical study if they satisfy any of the following criteria:; Those who are diagnosed with viral pneumonia caused by other than COVID-19 or bacterial pneumonia during the screening; Patients with severe pneumonia according to the WHO guidance; Have fever or signs of respiratory infections and; Satisfy any one of the following conditions: Respiratory rate > 30 breaths/min, severe respiratory distress, or room air oxygen saturation (SpO2) ≤ 93%; Patients with ARDS according to the WHO guidance; Those who have past medical histories described below:; Those who have medical histories of human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS), or hepatitis B or C viral infection; Those who cannot have a CT test done due to allergy to contrast agents, etc; Those who have comorbidities/symptoms described below:; Those who have a history or evidence of another clinically significant condition that may pose risks to patient safety or interfere with the study procedures, assessments or completion as determined by the investigator; Those who have moderate or severe renal impairment (eGFR < 60 mL/min/1.73 m2); Those who have moderate or severe hepatic impairment (Child-Pugh B or C, respectively); Patients who are being treated with corticosteroids or other immunosuppressants for asthma or autoimmune diseases at the entry of study are excluded, because these drugs counteract the action mechanism of EC-18 (PLAG); Those who have any abnormalities in laboratory tests described below:; Clinically significant liver function abnormality (Satisfy any one or more of the following):; Serum alanine aminotransferase (ALT) ≥ upper limit of normal (ULN) × 2.5; Serum aspartate aminotransferase (AST) ≥ ULN × 2.5; Serum total bilirubin ≥ ULN × 2.5; Patients with uncontrolled diabetes (HbA1c > 7.0%); Those who have hypersensitivity reactions to the IP and its components; Those who satisfy any of the descriptions below:; Pregnant or breastfeeding female subjects; Those who are planning on pregnancy or not using accepted contraception measures during the clinical study; Those who have participated in other clinical studies to receive IPs or apply investigational medical devices within 1 month from the time of obtaining the informed consent; Those who are considered to be ineligible to participate in the clinical study or have difficulty conducting this clinical study by the investigator; Those subjects with Hb < lower limit of normal (LLN) for males and females; Those subjects with a platelet count < LLN; Those subjects with a WBC < LLN

Helyszínek itt: Egyesült Államok

  • Lincoln Medical CenterThe Bronx, Egyesült ÁllamokContact: Maryanne GuerreroToborzás még nem indult
  • Kent County Memorial HospitalWarwick, Egyesült ÁllamokContact: Joni HarrisToborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

A trial of EC-18 in patients with mild/moderate pneumonia due to COVID-19

A vizsgálat 2 csoportja

  • Active EC-18A vizsgált kezelés

    Kezelés: EC-18

  • PlaceboPlacebo, összehasonlításként

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EC-18 in Preventing the Progression of COVID-19 Infection to Severe Pneumonia or ARDS
A regiszteradat frissítve
2026. október 21.